All News

RheumNow Podcast square

Want to Go Far, Go Together (4.21.2023)

Jack Cush, MD

This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.

Read Article
psA.fil_.toes_.jpg

Sex-Specific Differences in Psoriatic Arthritis

Jack Cush, MD

A systematic review of published literature on psoriatic arthritis (PsA), clinical features, disease activity, and patient-reported outcomes (PROs) shows generally higher levels of disease activity in women, compared to men with PsA.

Read Article
amgen.jpg

Amgen Wins Otezla Patent Case - Brand Protected till 2028

Reuters

Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028.

Read Article
warning, caution

EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks

Jack Cush, MD

The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.

Read Article
Preg2_0.jpg

Psoriatic Arthritis and Pregnancy

Eric Dein, MD

At RheumNow Live this weekend, Dr. Christina Chambers, an epidemiologist at the University of California San Diego and the principal investigator of MotherToBaby Pregnancy Studies, reviewed the available data on psoriatic arthritis and pregnancy. There is little evidence at this time that pregnancy affects PsA, though studies reliably demonstrate increase in disease activity in the post-partum period in both skin and joint disease.

Read Article
Join us April 18 for: Private Practice & Academia In this session, our panelists will address the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?". https://t.co/BrWG57mRRG https://t.co/A0pzEvJ3cu

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID had a significant effect on mental health of inflammatory rheumatic Dz (IRDs) pts. UK NHS survey of 639 IRD (70% RA, 16% PsA) saw 40% w/ mod/severe pandemic impact on physical & mental health; 29% w/ depression, 22% anxiety; affecting Women>males https://t.co/odUCjScMBZ https://t.co/Eb1E2In5z1

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective of 28,360 #PsA pts saw more comorbidities by race - AAs had signif. more HTN (59% vs 52%), DM (31% vs 23%), obesity (47% vs 30%) & gout (12% vs 8%); but whites more cancer (20% vs 16%), anxiety (28% vs 23%), OP(14% vs 12%), more biologic use https://t.co/YwGjVowO3G https://t.co/3BUXFX11rh

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now. https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC

Links:

Dr. John Cush RheumNow ( View Tweet)
Dutch Biologic Monitor surveys of RA, PsA, axSpA pts on etanercept or adalimumab, looked at adverse drug reactions. Among 748 consecutive pts on biologics, women had more ADRs (55%) than men (38%). nature ofreported ADRs differed betw sexes (p = 0.02). https://t.co/fGRgX4IJLR https://t.co/FJE7BrKPfQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Pooled data from 3 RCTs in PsA compared tofacitinib vs. adalimumab in 816 pts. Baseline, women had higher TJC, enthesitis, HAQ-DI, FACIT-F (Males more dactylitis). Sexes had equal ACR20/50/70, PASI75, ∆HAQ-DI, & persistence, but females less achieved MDA https://t.co/LICWVjI2kH https://t.co/8RipVIEWyJ

Links:

Dr. John Cush RheumNow ( View Tweet)
The Origin Story: Women in Rheumatology--The XX Factor When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field. https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL

Links:

Dr. John Cush RheumNow ( View Tweet)
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor. Sign up to attend our Tuesday Night Rheumatology series. @uptoTate @KDAO2011 https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN

Links:

Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology. Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations. https://t.co/OlP0pupkMV https://t.co/pZQMASafcG

Links:

Dr. John Cush RheumNow ( View Tweet)
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

Links:

Dr. John Cush RheumNow ( View Tweet)
Small trial of MTX vs Apremilast in PsA from India. OL, MD blinded RCT of 31 pts (26 completed). 15 APR vs 16 MTX (had more enthesitis, dactylitis); wk 24 responses favored MTX for major cDAPSA (37% vs 20%; p=0.4), ACR20 (56 v 47%;NS) w/ no diff in AE https://t.co/KIItKgCq4w https://t.co/FG3NV2yLuc

Links:

Dr. John Cush RheumNow ( View Tweet)
199 psoriasis Pts Rx w/ MTX monotherapy. Drug survival at 1, 2, & 5 yrs was 47, 36, & 29%; Avg MTX duration was 10.1 mos. Discontinuation mostly for AE (39.2%), ineffective (38.5%), PSO remission (12.2%). Durability best w/ ^age & dose >15 mg https://t.co/zKP0QCDzE2 https://t.co/35neGlhpE5

Links:

Dr. John Cush RheumNow ( View Tweet)
Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

Links:

Dr. John Cush RheumNow ( View Tweet)
Polypharmacy Increased in Psoriatic Arthritis Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA. https://t.co/vispc9ei51 https://t.co/s45Nmpf46P

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×